PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [68Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer

Frederik A. Verburg; David Pfister; Natascha I. Drude; Felix M. Mottaghy; Florian F. Behrendt

doi:10.3413/Nukmed-0917-17-07

Nuklearmedizin - NuclearMedicine, Table of Contents

Nuklearmedizin 2017; 56(06): 225-232
DOI: 10.3413/Nukmed-0917-17-07

Original Article

Schattauer GmbH

PSA levels, PSA doubling time, Gleason score and prior therapy cannot predict measured uptake of [⁶⁸Ga]PSMA-HBED-CC lesion uptake in recurrent/metastatic prostate cancer

PSA-Werte, PSA-Verdopplungszeit, Gleason Score und Therapiestatus liefern keine Vorhersage zur Traceranreicherung von [⁶⁸Ga]PSMA-HBED-CC bei von Patienten mit rezidiviertem und/oder metastasiertem PCA

Frederik A. Verburg

¹RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen, Germany

²University Hospital Marburg, Department of Nuclear Medicine, Marburg, Germany

,

David Pfister

⁴University Hospital Cologne, Department of Urology, Cologne, Germany

,

Natascha I. Drude

¹RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen, Germany

,

Felix M. Mottaghy

¹RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen, Germany

³Maastricht University Medical Center, Department of Nuclear Medicine, Maastricht, the Netherlands

,

Florian F. Behrendt

¹RWTH University Hospital Aachen, Department of Nuclear Medicine, Aachen, Germany

⁵Radiology Institute Aachen Land“, Würselen, Germany

› Author Affiliations

Abstract

Summary

Aim: To assess whether clinical prostate cancer (PCA) related factors and therapy status can predict the degree of tracer uptake on [⁶⁸Ga]PSMA-HBED-CC PET/CT.

Materials & methods: We retrospectively studied 124 patients with recurrent an/or metastatic PCA who underwent [⁶⁸Ga]PSMAHBED-CC PET/CT. The maximum standardized uptake value (SUVmax) was determined in the prostate bed as well as in three size categories (≤ 5 mm, > 5–15 mm, > 15 mm) in pelvic lymph node, extrapelvic lymph node, bone and visceral metastases.

Results: Significant positive correlations between lesion size and SUVmax were found in pelvic lymph node metastases > 5 -≤15 mm (Spearmans rho = 0.502, p = 0.002) as well as in extrapelvic lymph node metastases5 mm (rho = 0.314, p = 0.033) and > 5 ≤-15 mm (rho = 0.614, p < 0.001). SUVmax tended to be higher in the largest diameter category in each anatomic station than in the middle and lower categories. We were unable to find evidence for a relationship between SUVmax and PSA, PSAdt, Gleason score, androgen deprivation therapy, radiation therapy or chemotherapy status.

Conclusion: Measured tracer uptake in [⁶⁸Ga]PSMA-HBED-CC PET/CT in patients with recurrent/metastasized prostate cancer is significantly influenced by lesion size as a result of partial volume effects in the very small lesions. Clinical indicators of aggressive prostate cancer behaviour such as PSA levels, PSA doubling time or the Gleason score of the primary tumour, as well as the androgen deprivation therapy, radiation therapy or chemotherapy status are not related to measured tracer uptake.

Zusammenfassung

Ziel: Beantwortung der Frage ob klinisch bestimmbare Faktoren und Therapiestatus bei Prostatakarzinom (PCA) eine Vorhersage zur Traceranreicherung in [⁶⁸Ga]PSMA-HBED-CC PET/CT liefern können.

Material & Methoden: 124 Patienten mit rezidiviertem und/oder metastasiertem PCA die [⁶⁸Ga]PSMA-HBED-CC PET/CT untergingen, wurden retrospektiv untersucht. Der maximum Standardized Uptake Value (SUVmax) wurde in der Prostataloge gemessen sowie in drei Größen-Kategorien ( 5 mm, > 5–15 mm, > 15 mm) in Metastasen in den pelvinen Lymphknoten-, extrapelvinen Lymphknoten-, Knochen- und viszeralen Metastasen. Ergebnisse: Signifikant positive Korrelationen zwischen Läsionsgröße und SUVmax wurden in pelvinen Lymphknotenmetastasen > 5 -≤15 mm (Spearmans rho = 0.502, p = 0.002), extrapelvinen Lymphknotenmetastasen5 mm (rho = 0.314, p = 0.033) und > 5 -≤15 mm (rho = 0.614, p < 0.001) gefunden. Für jede anatomische Lokalisation wurde ein höherer Wert SUVmax innerhalb der größten Kategorie verglichen zu mittleren und kleinsten Kategorie gefunden.

Keywords

PSA - PSA doubling time - Gleason score - prostate cancer - [⁶⁸Ga]PSMA-HBED-CC PET/CT

Schlüsselwörter

PSA - PSA-Verdopplungszeit - Gleason Score - Prostatakarzinom - [⁶⁸Ga]PSMA-HBED-CC PET/CT

Full Text

References

References
1 Afshar-Oromieh A, Avtzi E, Giesel FL. et al. The diagnostic value of PET/CT imaging with the (68)Ga-labelled PSMA ligand HBED-CC in the diagnosis of recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 197-209.
2 Afshar-Oromieh A, Malcher A, Eder M, Eisenhut M, Linhart HG, Hadaschik BA, Holland-Letz T, Giesel FL, Kratochwil C, Haufe S, Haberkorn U, Zechmann CM. PET imaging with a [⁶⁸Ga]gallium-labelled PSMA ligand for the diagnosis of prostate cancer: biodistribution in humans and first evaluation of tumour lesions. Eur J Nucl Med Mol Imaging 2013; 40: 486-495.
3 Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP. Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases. Cancer 1998; 82: 2256-2261.
4 Ceci F, Uprimny C, Nilica B. et al. Ga-PSMA PET/ CT for restaging recurrent prostate cancer: which factors are associated with PET/CT detection rate?. Eur J Nucl Med Mol Imaging 2015; 42: 1284-1294.
5 Demirci E, Ocak M, Kabasakal L, Decristoforo C, Talat Z, Halac M, Kanmaz B. (68)Ga-PSMA PET/ CT imaging of metastatic clear cell renal cell carcinoma. Eur J Nucl Med Mol Imaging 2014; 41: 1461-1462.
6 Eder M, Schafer M, Bauder-Wust U, Hull WE, Wangler C, Mier W, Haberkorn U, Eisenhut M. ⁶⁸Ga-complex lipophilicity and the targeting property of a urea-based PSMA inhibitor for PET imaging. Bioconjug Chem 2012; 23: 688-697.
7 Eiber M, Maurer T, Souvatzoglou M. et al. Evaluation of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in 248 Patients with Biochemical Recurrence After Radical Prostatectomy. J Nucl Med 2015; 56: 668-674.
8 Einspieler I, Rauscher I, Duwel C, Kronke M, Rischpler C, Habl G, Dewes S, Ott A, Wester HJ, Schwaiger M, Maurer T, Eiber M. Detection Efficacy of Hybrid ⁶⁸Ga-PSMA Ligand PET/CT in Prostate Cancer Patients with Biochemical Recurrence After Primary Radiation Therapy Defined by Phoenix Criteria. J Nucl Med 2017; 58: 1081-1087.
9 Giesel FL, Fiedler H, Stefanova M, Sterzing F, Rius M, Kopka K, Moltz JH, Afshar-Oromieh A, Choyke PL, Haberkorn U, Kratochwil C. PSMA PET/CT with Glu-urea-Lys-(Ahx)-[Ga(HBEDCC)] versus 3D CT volumetric lymph node assessment in recurrent prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 1794-1800.
10 Hanscheid H, Sweeney RA, Flentje M, Buck AK, Lohr M, Samnick S, Kreissl M, Verburg FA. PET SUV correlates with radionuclide uptake in peptide receptor therapy in meningioma. Eur J Nucl Med Mol Imaging 2012; 39: 1284-1288.
11 Kabasakal L, Demirci E, Ocak M, Akyel R, Nematyazar J, Aygun A, Halac M, Talat Z, Araman A. Evaluation of PSMA PET/CT imaging using a ⁶⁸Ga-HBED-CC ligand in patients with prostate cancer and the value of early pelvic imaging. Nucl Med Commun 2015; 42: 987-988.
12 Kratochwil C, Giesel FL, Eder M, Afshar-Oromieh A, Benesova M, Mier W, Kopka K, Haberkorn U. [Lu]Lutetium-labelled PSMA ligand-induced remission in a patient with metastatic prostate cancer. Eur J Nucl Med Mol Imaging 2015; 42: 987-988.
13 Krohn T, Birmes A, Winz OH, Drude NI, Mottaghy FM, Behrendt FF, Verburg FA. The reconstruction algorithm used for [⁶⁸Ga]PSMA-HBED-CC PET/CT reconstruction significantly influences the number of detected lymph node metastases and coeliac ganglia. Eur J Nucl Med Mol Imaging 2017; 44: 662-669.
14 Krohn T, Verburg FA, Pufe T, Neuhuber W, Vogg A, Heinzel A, Mottaghy FM, Behrendt FF. [(68)Ga]PSMA-HBED uptake mimicking lymph node metastasis in coeliac ganglia: an important pitfall in clinical practice. Eur J Nucl Med Mol Imaging 2015; 42: 210-214.
15 Mannweiler S, Amersdorfer P, Trajanoski S, Terrett JA, King D, Mehes G. Heterogeneity of prostate-specific membrane antigen (PSMA) expression in prostate carcinoma with distant metastasis. Pathol Oncol Res 2009; 15: 167-172.
16 Marchal C, Redondo M, Padilla M, Caballero J, Rodrigo I, Garcia J, Quian J, Boswick DG. Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia. Histol Histopathol 2004; 19: 715-718.
17 Meller B, Bremmer F, Sahlmann CO, Hijazi S, Bouter C, Trojan L, Meller J, Thelen P. Alterations in androgen deprivation enhanced prostate-specific membrane antigen (PSMA) expression in prostate cancer cells as a target for diagnostics and therapy. EJNMMI Res 2015; 5: 66.
18 Ross JS, Sheehan CE, Fisher HA, Kaufman Jr RP, Kaur P, Gray K, Webb I, Gray GS, Mosher R, Kallakury BV. Correlation of primary tumor prostate-specific membrane antigen expression with disease recurrence in prostate cancer. Clin Cancer Res 2003; 9: 6357-6362.
19 Rowe SP, Gage KL, Faraj SF. et al. (1)(8)F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer. J Nucl Med 2015; 56: 1003-1010.
20 Sachpekidis C, Eder M, Kopka K, Mier W, Hadaschik BA, Haberkorn U, Dimitrakopoulou-Strauss A. Ga-PSMA-11 dynamic PET/CT imaging in biochemical relapse of prostate cancer. Eur J Nucl Med Mol Imaging 2016; 41: e473-e479.
21 Sahlmann CO, Meller B, Bouter C, Ritter CO, Strobel P, Lotz J, Trojan L, Meller J, Hijazi S. Biphasic (6)(8)Ga-PSMA-HBED-CC-PET/CT in patients with recurrent and high-risk prostate carcinoma. Eur J Nucl Med Mol Imaging 2016; 43: 898-905.
22 Schmittgen TD, Teske S, Vessella RL, True LD, Zakrajsek BA. Expression of prostate specific membrane antigen and three alternatively spliced variants of PSMA in prostate cancer patients. Int J Cancer 2003; 107: 323-329.
23 Silver DA, Pellicer I, Fair WR, Heston WD, Cordon-Cardo C. Prostate-specific membrane antigen expression in normal and malignant human tissues. Clin Cancer Res 1997; 3: 81-85.
24 Sobin LH, Gospodarowicz MK, Wittekind C. TNM classification of malignant tumours. 7th ed. New-York: Wiley-Blackwell,; 2009
25 Stewart SB, Cheville JC, Sebo TJ. et al. Gleason grading after neoadjuvant hormonal therapy retains prognostic value for systemic progression following radical prostatectomy. Prostate Cancer Prostatic Dis 2014; 17: 332-337.
26 Uprimny C, Kroiss AS, Decristoforo C, Fritz J, von Guggenberg E, Kendler D, Scarpa L, di Santo G, Roig LG, Maffey-Steffan J, Horninger W, Virgolini IJ. ⁶⁸Ga-PSMA-11 PET/CT in primary staging of prostate cancer: PSA and Gleason score predict the intensity of tracer accumulation in the primary tumour. Eur J Nucl Med Mol Imaging 2017; 44: 941-949.
27 Verburg FA, Krohn T, Heinzel A, Mottaghy FM, Behrendt FF. First evidence of PSMA expression in differentiated thyroid cancer using [Ga]PSMAHBED-CC PET/CT. Eur J Nucl Med Mol Imaging 2015; 42: 1622-1623.
28 Verburg FA, Pfister D, Heidenreich A, Vogg A, Drude NI, Voo S, Mottaghy FM, Behrendt FF. Extent of disease in recurrent prostate cancer determined by [Ga]PSMA-HBED-CC PET/CT in relation to PSA levels, PSA doubling time and Gleason score. Eur J Nucl Med Mol Imaging 2015; 43: 397-403.
29 Zielinski A, Behrendt FF, Verburg FA, Mottaghy FM, Krohn T. Phantom studies and clinical application of high resolution, image reconstruction using (18)F-fluoromethylcholine PET/CT for prostate cancer. Hell J Nucl Med 2014; 17: 194-199.